VM Oncology, LLC is recruiting patients for a PHASE1/PHASE2 clinical trial testing pembrolizumab (Keytruda) for mesothelioma.
The trial, designated NCT03556228, aims to enroll up to 242 participants at 15 sites, including locations in California, Connecticut, District of Columbia.
About the Study
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists
Treatment Approach
This trial uses a PD-1 checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
Key trial details:
- Phase: PHASE1/PHASE2
- Sponsor: VM Oncology, LLC
- Enrollment target: 242
- Status: RECRUITING
Why This Trial Matters
Study Locations
The trial is recruiting at:
- Providence Medical Foundation (site 209), California
- Hartford Hospital (site 210), Connecticut
- The George Washington University Cancer Center (site 212), District of Columbia
- Holy Cross Hospital (site 213), Florida
- Memorial Cancer Institute at Memorial Healthcare Systems (site 132), Florida
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening